clinical trial · NCT07750990
An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD)
Pompe DiseaseS-606001ERT
brief summary
The primary purpose of this study is to evaluate the long-term safety and tolerability profile of S-606001 in participants with LOPD. Participants who completed other S-606001 studies (for example, NCT07123155), including participants in a S-606001 study whose allocated arm was terminated by the sponsor and who are willing to participate in this study, will be enrolled globally.
started
Aug 31, 2026
primary completion
Aug 31, 2028
completion
Aug 31, 2028
last updated
Aug 6, 2026
official title
A Phase 2, Open-label, Multicenter, Extension Study to Investigate the Long-term Safety and Efficacy of S-606001 in Patients With Late-onset Pompe Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol